Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Clinical Trials

Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Liver Cancer
Hepatocellular Carcinoma

Interventions: Procedure: LT
Drug: ADV-TK
Drug: ganciclovir

First Posted Date: 2014-07-29

Last Posted Date: 2014-07-29

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 81

Registration Number: NCT02202564

PTH - Preemptive Treatment for Herpesviridae

Phase 4

Completed

Conditions: Viral Pneumonia

Interventions: Drug: Ganciclovir
Drug: Placebo
Drug: Aciclovir

First Posted Date: 2014-06-02

Last Posted Date: 2023-04-06

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 317

Registration Number: NCT02152358

Locations: 🇫🇷
Assistance Publique - Hôpitaux de Marseille, Marseille, France

Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis

Not Applicable

Completed

Conditions: Cytomegalovirus Anterior Segment Infection
Endotheliitis
Anterior Uveitis

Interventions: Drug: Ganciclovir

First Posted Date: 2012-07-23

Last Posted Date: 2015-11-18

Lead Sponsor: Singapore National Eye Centre

Target Recruit Count: 29

Registration Number: NCT01647529

Locations: 🇸🇬
Singapore National Eye Centre, Singapore, Singapore

Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus

Phase 3

Conditions: Conjunctivitis
Adenovirus.

Interventions: Drug: Ophthalmic gel (placebo)
Drug: Ganciclovir

First Posted Date: 2012-05-17

Last Posted Date: 2012-05-17

Lead Sponsor: Adapt Produtos Oftalmológicos Ltda.

Target Recruit Count: 22

Registration Number: NCT01600365

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

Phase 4

Completed

Conditions: Viral Shedding
Keratoconjunctivitis Due to Adenovirus

Interventions: Drug: genteal gel
Drug: Zirgan

First Posted Date: 2012-02-15

Last Posted Date: 2018-02-28

Lead Sponsor: Lifelong Vision Foundation

Target Recruit Count: 20

Registration Number: NCT01533480

Locations: 🇺🇸
Lifelong Vision Foundation, Chesterfield, Missouri, United States

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

Not Applicable

Completed

Conditions: Conjunctivitis, Viral
Adenoviridae Infections

Interventions: Drug: Artificial tear
Drug: Ganciclovir

First Posted Date: 2011-05-06

Last Posted Date: 2011-05-06

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 33

Registration Number: NCT01349452

Locations: 🇧🇷
Federal University of Sao Paulo, São Paulo, Brazil

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

Phase 2

Completed

Conditions: Acute Lung Injury
Acute Respiratory Distress Syndrome
Respiratory Failure

Interventions: Drug: IV Ganciclovir
Drug: Placebo

First Posted Date: 2011-04-15

Last Posted Date: 2018-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01335932

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 11 locations

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Completed

Conditions: Anaplastic Large Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma
Noncontiguous Stage II Grade 3 Follicular Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Splenic Marginal Zone Lymphoma

Interventions: Procedure: infection prophylaxis and management
Other: laboratory biomarker analysis
Other: flow cytometry
Genetic: DNA analysis
Genetic: RNA analysis
Procedure: management of therapy complications
Drug: ganciclovir
Drug: valganciclovir
Drug: foscarnet sodium
Procedure: antiviral therapy
Genetic: polymerase chain reaction
Genetic: protein expression analysis